Somatically mutated ABL1 is an actionable and essential NSCLC survival gene

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Non-small cell lung cancer (NSCLC) therapy is challenged by a scarcity of actionable mutations.
• Identifying novel genetic dependencies is crucial for developing targeted treatments for NSCLC.

Purpose of the Study:

• To identify genetic dependencies in NSCLC.
• To investigate the role of mutated ABL1 in NSCLC cell survival and response to ABL inhibitors.

Main Methods:

• Genetic screening to identify NSCLC dependencies.
• In vitro assays to assess sensitivity to ABL inhibitors.
• In vivo studies using mouse models of NSCLC.
• Structural modeling and analysis of ABL1 mutations.

Main Results:

• Somatically mutated ABL1 was identified as essential for NSCLC cell survival.
• NSCLC cells with ABL1 mutations showed sensitivity to ABL inhibitors, including imatinib.
• Imatinib suppressed tumor growth in vivo in NSCLC models with ABL1 gain-of-function mutations.
• ABL1 mutations increased downstream pathway activation and promoted cytosolic localization, correlating with oncogenic properties.

Conclusions:

• Mutated ABL1 represents a targetable vulnerability in NSCLC.
• ABL1 inhibitors, such as imatinib, demonstrate efficacy against NSCLC harboring specific ABL1 mutations.
• Patients with NSCLC and ABL1 mutations may benefit from stratification for imatinib-based combination therapies.